Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection.
Kirkpatrick, Lynn, Linda A Pestano, Cari Evans, Jeffrey Millard, Jeffrey Levy, Vanessa Zann, Katie Pepper, and William K Schmidt. 2026. “Formulation Development and a Phase 1 Clinical Study of PF614-MPAR, an Oxycodone Prodrug With Oral Opioid Overdose Protection.”. Journal of Opioid Management 22 (1): 37-A26.